Outcomes of Placenta Accreta Spectrum Disorders Surgery in Relation to Placenta Accreta Scoring Index
NCT ID: NCT06220760
Last Updated: 2025-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
154 participants
OBSERVATIONAL
2024-02-20
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Association of Ultrasonographic Parameters With FIGO Clinical Grading System for Placenta Accreta Spectrum
NCT04801706
Evaluation of Planned Conservative Surgical Management of Placenta Accreta Spectrum in Women's Health Center, Assiut University Hospital
NCT06712576
Placenta Accreta Index Score in Placenta Accreta Spectrum
NCT05513092
Management of Placenta Accreta Spectrum
NCT04609527
Ultrasound Model to Help Differentiate Between Placenta Accreta Spectrum and Uterine Dehiscence in 3rd Trimester Pregnancies
NCT07236060
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This increase is due to many factors. A scar of previous uterine surgery is a major risk factor for placenta accreta. Caesarean section scar is the most common one of uterine scars according to \[4\] especially in presence of placenta previa where the risk of placenta accreta was 3%, 11%, 40%, 61%, and 67% for the first, second, third, fourth, and fifth or greater repeat cesarean deliveries, respectively. \[5\] reported that both cesarean delivery morbidity and placenta accreta were positively associated with age \>30 years. Previous myomectomy, multi parity, vigorous curettage are other risk factors as said \[6\]. More ever sub mucous leiomyoma and thermal ablation are also contributing factors to Placenta accreta \[7\] and lastly \[8\] said that uterine artery embolization is considered as a risk factor for occurrence of placenta accreta. Contrarily, inter pregnancy interval more than 60 months was associated with decreased risk of placenta accreta \[9\].
Because placenta accreta can lead to life-threatening blood loss, identification of these high-risk patients would be helpful in management of the pregnancy in addition to enabling the surgeon to be prepared adequately before the time of delivery. Many studies have been done on identification of placenta accreta in the third trimester by 2D ultrasound and color Doppler. There are many modalities for detection of placenta accreta ante natally \[10\] used 2D ultrasound and color doppler for detection of placenta accreta in 3rd trimester with sensitivity and specificity; 95.24% and 94.74% respectively for ultrasound with the most prominent feature presence of multiple lakes that represented dilated vessels extending from the placenta through the myometrium. For Doppler, the most prominent feature was the presence of interphase hypervascularity with abnormal vessels linking the placenta to the bladder, and the rate was 95.24%.
As for surgery for placenta accreta, planned caesarean hysterectomy is recommended to reduce mortality and morbidity, but fertility is lost. Antenatal diagnosis of placenta accreta spectrum (PAS) can ensure multidisciplinary management at center of excellence which can reduce maternal and fetal complications. This can be established by a scoring system which provides a standardized criterion for the diagnosis and management Placenta Accreta Index (PAI).
Instead of adhering to the conventional approach that involves an elective caesarean hysterectomy based on antenatal imaging, more suitable approaches should be considered from the spectrum of hemostatic and fertility-preserving options available. In our study we will investigate if the degree of adherence is related to the PAI score. Therefore, we can predict cases which will need conservative surgery or peripartum hysterectomy. And so that the surgeon be preplanned to do either hysterectomy or conservative surgery
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ultrasound
The use of US to calculate placenta accreta index
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. singleton pregnancy
3. known to have placenta previa (lower edge of the placenta within 5 cm from internal Os )
4. with at least previous 1 cesarean section
Exclusion Criteria
2. haemodynamically unstable
18 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammed Nagy Zaki
Clinical professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohammed Nagy, MD
Role: STUDY_CHAIR
Assiut University
Mansour Khalifa, MD
Role: STUDY_DIRECTOR
Assiut University
Mostafa Hussien, MD
Role: PRINCIPAL_INVESTIGATOR
Assiut University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assiut University
Asyut, Asyut Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
US in Placenta accreta
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.